{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T10:44:28Z","timestamp":1781347468436,"version":"3.54.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.micpath.2025.107805","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T23:28:27Z","timestamp":1749770907000},"page":"107805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Update on the management of HDV infection: current events and perspectives"],"prefix":"10.1016","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8685-5434","authenticated-orcid":false,"given":"Biagio","family":"Pinchera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Trucillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"D'Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Iuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Ametrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzia","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Riccardo","family":"Buonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.micpath.2025.107805_bib1","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.micpath.2025.107805_bib2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis","volume":"68","author":"Chen","year":"2019","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.micpath.2025.107805_bib3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and metaanalysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.micpath.2025.107805_bib4","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.micpath.2025.107805_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11739-019-02163-8","article-title":"Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study","volume":"15","author":"Di Minno","year":"2020","journal-title":"Intern Emerg Med"},{"issue":"5","key":"10.1016\/j.micpath.2025.107805_bib6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40620-019-00608-z","article-title":"Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection","volume":"32","author":"Coppola","year":"2019","journal-title":"J. Nephrol."},{"issue":"5","key":"10.1016\/j.micpath.2025.107805_bib7","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1071\/SH17168","article-title":"Prevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: results from a prospective study","volume":"15","author":"Gentile","year":"2018","journal-title":"Sex. Health"},{"issue":"10","key":"10.1016\/j.micpath.2025.107805_bib8","article-title":"Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis","volume":"4","author":"Palom","year":"2022","journal-title":"D JHEP Rep"},{"issue":"S1","key":"10.1016\/j.micpath.2025.107805_bib9","article-title":"Hepatitis delta virus reflex testing in patients with hepatitis B improves the HDV screening cascade: 10 years of real-world experience from Avicenne University Hospital, France","volume":"77","author":"Brichler","year":"2022","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.micpath.2025.107805_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0016-5085(99)70563-9","article-title":"Changing pattern of chronic hepatitis D in southern Europe","volume":"117","author":"Rosina","year":"1999","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.micpath.2025.107805_bib11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7326\/0003-4819-98-4-437","article-title":"Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment","volume":"98","author":"Rizzetto","year":"1983","journal-title":"Ann. Intern. Med."},{"issue":"10","key":"10.1016\/j.micpath.2025.107805_bib12","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.micpath.2025.107805_bib13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.21873\/invivo.11456","article-title":"Severe vitamin D deficiency increases mortality among patients with liver cirrhosis regardless of the presence of HCC","volume":"33","author":"Buonomo","year":"2019","journal-title":"In Vivo"},{"issue":"3","key":"10.1016\/j.micpath.2025.107805_bib14","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1478-3231.2009.02140.x","article-title":"Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis","volume":"30","author":"Zachou","year":"2010","journal-title":"Liver Int."},{"key":"10.1016\/j.micpath.2025.107805_bib15","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jhep.2020.06.038","article-title":"Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta","volume":"73","author":"Roulot","year":"2020","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.micpath.2025.107805_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092062","article-title":"High serum levels of HDV-RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta","volume":"9","author":"Romeo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.micpath.2025.107805_bib17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/apt.15521","article-title":"Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia","volume":"51","author":"Palom","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.micpath.2025.107805_bib18","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/jvh.13366","article-title":"Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta","volume":"27","author":"Wranke","year":"2020","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.micpath.2025.107805_bib19","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/jmv.25411","article-title":"Non-F HBV\/HDV-3 coinfection is associated with severe liver disease in Western Brazilian Amazon","volume":"91","author":"Da Silva","year":"2019","journal-title":"J. Med. Virol."},{"issue":"6","key":"10.1016\/j.micpath.2025.107805_bib20","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jhep.2019.12.028","article-title":"Hepatitis delta genotype 5 is associated with favorable disease outcome and better response to treatment compared to genotype 1","volume":"72","author":"Spaan","year":"2020","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.micpath.2025.107805_bib21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cgh.2005.12.007","article-title":"The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence","volume":"4","author":"El-Serag","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.micpath.2025.107805_bib22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/hep.24418","article-title":"Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis","volume":"54","author":"Berzigotti","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.micpath.2025.107805_bib23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/hep.20944","article-title":"Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus\/hepatitis C virus-coinfected patients","volume":"43","author":"Raimondo","year":"2006","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.micpath.2025.107805_bib24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jhep.2016.10.007","article-title":"Swiss HIV Cohort Study. Hepatitis delta-associated mortality in HIV\/HBV-coinfected patients","volume":"66","author":"B\u00e9guelin","year":"2017","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.micpath.2025.107805_bib25","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jhep.2022.06.010","article-title":"Bulevirtide with or without pegIFNa for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies","volume":"77","author":"Lampertico","year":"2022","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.micpath.2025.107805_bib27","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1097\/TP.0000000000004138","article-title":"Liver transplantation in hepatitis B\/hepatitis D (delta) virus coinfected recipients","volume":"106","author":"Martini","year":"2022","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.micpath.2025.107805_bib28","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.micpath.2025.107805_bib29","first-page":"CD006002","article-title":"Interferon alpha for chronic hepatitis D","volume":"2011","author":"Abbas","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.micpath.2025.107805_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104995","article-title":"Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: a meta-analysis","volume":"185","author":"Abdrakhman","year":"2021","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.micpath.2025.107805_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.micpath.2025.107805_bib32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107805_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/apt.12788","article-title":"Long-term therapy of chronic delta hepatitis with peginterferon alfa","volume":"40","author":"Heller","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.micpath.2025.107805_bib34","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/infdis\/jix656","article-title":"Interferon treatment duration in patients with chronic delta hepatitis and its effect on the natural course of the disease","volume":"217","author":"Yurdaydin","year":"2018","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.micpath.2025.107805_bib35","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2013.07.005","article-title":"Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study","volume":"59","author":"Manesis","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.micpath.2025.107805_bib36","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.21296","article-title":"Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta","volume":"44","author":"Niro","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.micpath.2025.107805_bib37","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hep.28876","article-title":"Antiviral treatment and liver-related complications in hepatitis delta","volume":"65","author":"Wranke","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.micpath.2025.107805_bib38","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"eLife"},{"issue":"4","key":"10.1016\/j.micpath.2025.107805_bib39","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jhep.2022.05.023","article-title":"Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread","volume":"77","author":"Zhang","year":"2022","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.micpath.2025.107805_bib40","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S0618-8278(19)30141-0","article-title":"Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEGinterferon Alpha 2a in patients with chronic HBV\/HDV co-infection","volume":"70","author":"Wedemeyer","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.micpath.2025.107805_bib41","article-title":"Safety and efficacy of bulevirtide monotherapy and in combination with peginterferon alfa-2a in patients with chronic hepatitis delta: 24 Weeks interim data of MYR204 phase 2b study","volume":"75","author":"Asselah","year":"2021","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.micpath.2025.107805_bib42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107805_bib43","first-page":"S294. LBP","article-title":"Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24-week interim data of the phase 3 MYR301 study","volume":"75","author":"Wedemeyer","year":"2021","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.micpath.2025.107805_bib44","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J. Hepatol."},{"issue":"LP36","key":"10.1016\/j.micpath.2025.107805_bib45","article-title":"Early clinical and virological changes in HDV patients with advanced cirrhosis treated with bulevirtide monotherapy in a reallife setting","volume":"74","author":"Loglio","year":"2021","journal-title":"Hepatology"},{"issue":"25","key":"10.1016\/j.micpath.2025.107805_bib46","first-page":"S0168","article-title":"Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis","author":"Degasperi","year":"2025","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.micpath.2025.107805_bib47","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2021.12.030","article-title":"Mathematical modeling suggests that entry-inhibitor bulevirtide may interfere with hepatitis D virus clearance from circulation","volume":"76","author":"Shekhtman","year":"2022","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.micpath.2025.107805_bib48","article-title":"Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations","volume":"6","author":"Shekhtman","year":"2023","journal-title":"JHEP Rep"},{"issue":"abstract 21","key":"10.1016\/j.micpath.2025.107805_bib49","article-title":"Safety and efficacy of 2mg bulevirtide in patients with chronic HBV\/HDV co-infection. first real-world results (French early access program)","volume":"74","author":"De Ledinghen","year":"2021","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.micpath.2025.107805_bib50","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1111\/liv.15330","article-title":"T-cell drive allergic cutaneous reaction complicating treatment of hepatitis delta virus infection with bulevirtide","volume":"42","author":"Behrend","year":"2022","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.micpath.2025.107805_bib51","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jhep.2022.03.004","article-title":"Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV\/HDV-associated compensated cirrhosis","volume":"77","author":"Schwarz","year":"2022","journal-title":"J. Hepatol."},{"issue":"24","key":"10.1016\/j.micpath.2025.107805_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415924","article-title":"Metabolic effect of blocking sodium-taurocholate Co-transporting polypeptide in hypercholesterolemic humans with a twelve-week course of bulevirtide\u2014an exploratory phase I clinical trial","volume":"23","author":"Stoll","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.micpath.2025.107805_bib53","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11894-023-00901-9","article-title":"Hepatitis D virus and HBsAg dynamics in the era of new antiviral treatments","volume":"25","author":"Shekhtman","year":"2023","journal-title":"Curr. Gastroenterol. Rep."}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401025005303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401025005303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T18:51:12Z","timestamp":1752000672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401025005303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":52,"alternative-id":["S0882401025005303"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2025.107805","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on the management of HDV infection: current events and perspectives","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2025.107805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107805"}}